Possibilities of combined PET/CT with 18F-FDG in evaluating the effectiveness of targeted therapy in patients with non-small cell lung cancer

Author:

Strutynsky V. A.1ORCID,Sinitsyn V. E.1ORCID,Roytberg G. E.2ORCID,Platonova O. E.3ORCID

Affiliation:

1. Medical Research and Education Center of M.V. Lomonosov Moscow State University, Faculty of Fundamental Medicine

2. Pirogov Russian National Research Medical University, School of Continuing Medical Education

3. Joint-stock company “Medicine”

Abstract

Introduction. Early assessment of the effect of targeted therapy in patients with non-small cell lung cancer (NSCLC) and a mutation in the EGFR gene is important for the timely correction of antitumor therapy.Aim: To study the possibilities of combined positron emission and computed tomography with 18F-fluorodeoxyglucose (PET/ CT with 18F-FDG) using the RECIST 1.1 and PERCIST 1.0 criteria. In a comparative assessment of the effect of various targeted therapy options in patients with NSCLC and a mutation in the EGFR gene.Material and Methods. The study included 86 patients with stage II-IV NSCLC, including 56 patients with a mutation in the EGFR gene. Of these, 32 patients received targeted monotherapy with tyrosine kinase inhibitors (TKI) – gefitinib or erlotinib and 24 patients received combination therapy (TKI + bevacizumab). The control group consisted of 30 patients who received platinum-containing chemotherapy drugs in combination with bevacizumab. The effect of antitumor therapy was evaluated using the combined PET method/CT with 18F-FDG using RECIST 1.1 and PERCIST 1.0 criteria. The results of the study were compared before the start of treatment and after 4-6 weeks of treatment.Results. In the repeated study of PET/CT with 18F-FDG, a partial positive response to the treatment of both tumor foci and affected regional lymph nodes according to the metabolic criteria PERCIST 1.0. was observed 1.3–1.8 times more often than when using the anatomical criteria RECIST 1.1. (p = 0,049). The frequency of а positive response to treatment in patients receiving targeted monotherapy was quite comparable to that in patients in the control group (43.7 and 40.0%, respectively). Based on 18F-FDG repeat PET/CT and PERCIST 1.0 metabolic criteria in patients receiving combined targeted therapy, a partial positive effect of treatment (58.3%) was observed 1.4 times more often, and disease progression was 4 times less common than in the subgroup of targeted monotherapy and in the control group (p = 0,043).Conclusions. Possibilities of early assessment of the effect of antitumor therapy using PET/CT with 18F-FDG increase when using the metabolic criteria PERCIST 1.0 – more sensitive than the anatomical criteria RECIST 1.1. According to PET/CT with 18F-FDG in patients with NSCLC and a mutation in the EGFR gene, the effect of combined therapy of TKI in combination with bevacizumab significantly exceeds not only the result of targeted monotherapy, but also the effect of chemotherapeutic treatment of patients in the control group.

Publisher

Cardiology Research Institute

Subject

Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine

Reference20 articles.

1. Kaprina A.D., Starinsky V.V., Shahzadova A.O.; ed. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: PA Herzen Moscow Research Institute of Oncology – branch of National Medical Research Center for Radiology Ministry of Health of the Russian Federation; 2020:252. (In Russ.)

2. Meshcheryakova N.A. Positron emission tomography combined with computed tomography, in diagnosis and evaluation of effectiveness of treatment of non-small cell lung cancer: Autoabstract thesis for candidate of medical sciences (14.01.12, 14.01.13). National Medical Research Center of Oncology named after N.N. Blokhin of the Ministry of Health of the Russian Federation. Moscow; 2017:26. (In Russ.)

3. Andreev D.A., Zav’yalov A.A., Kokushkin K.A., Davydovskaya M.V. The application of the modern targeted medications for the treatment of metastatic rectal cancer. Evidence-based Gastroenterology. 2018;7(2):21–29. (In Russ.) DOI: 10.17116/dokgastro20187221.

4. Borisova E.I., Gutorov S.L., Abramov M.E. Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case. Meditsinskiy sovet = Medical Council. 2019;(19):38–43. (In Russ.) DOI: 10.21518/2079-701X-2019-19-38-43.

5. Dai D., Xu W., Wang Q., Li X., Zhu Y. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance Prediction]. Zhongguo Fei Ai Za Zhi. 2017;20(12):852–856. (In Chinese). DOI: 10.3779/j.issn.1009-3419.2017.12.10.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3